Our manuscript titled “A prolyl oligopeptidase inhibitor, KYP-2047, reduces α-synuclein protein levels and aggregates in cellular and animal models of Parkinson’s disease” has been accepted for publication in British Journal of Pharmacology (impact factor 4.9)!

In the manuscript, we showed using α-synuclein overexpressing cells and animal models that even a short term treatment with a prolyl oligopeptidase (PREP) inhibitor (KYP-2047) significantly reduced the aggregation of α-synuclein. This is an important step on studying the role of PREP on α-synuclein aggregation process and Parkinson’s disease.

The abstract of the publication can be found here.